The MEK inhibitor selumetinib is FDA approved for treating nervous system tumors in patients with syndromic neurofibromatosis type 1 (NF-1) harboring a germline NF1 mutation (13, 14). Here, MAP2K7 is linked to nervous system neoplasm.